anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
FIELD: experimental medicine, pharmacology, phytotherapy. SUBSTANCE: invention proposes to use coneflower purple (Echinacea) and a composition on its base that involves coneflower purple dried extract, pectin and ascorbic acid (vitamin C) taken at the following ratio of components, wt.-%: coneflower purple dried extract 15-70; pectin 20-80, and ascorbic acid 1-10. Agent prepared of plant raw shows an adaptogenic activity and broad pattern of therapeutic (curative-prophylaxis) effect. Agent can be used as drugs, food additions enhancing total nonspecific resistance of organism at different short-time and prolonged extreme effects. EFFECT: enhanced effectiveness of an agent. 2 cl, 10 tbl, 10 ex
Patients undergo TTFields therapy over 18-24 hours daily. Cycles repeat every 4 weeks for 12 months in the absence of disease progression or unacceptable toxicity.
The biological effects of the cytokine TNF are mediated by binding to receptors on the surface of cells. This disclosure describes new proteins and polynucleotides that promote enzymatic cleavage and release of TNF receptors. The nucleotide sequence must be selected from SEQ. ID NOs: 1 to 10. Also provided are methods for identifying additional compounds that influence TNF receptor shedding. As the active ingredient in a pharmaceutical composition, the products of this invention increase or decrease TNF signal transduction, thereby alleviating the pathology of disease.
The invention discloses an epicaivirus isolate, an epicaivirus inactivated vaccine and a preparation method thereof. The porcine Seneca virus CH-HLJ strain is obtained by separating from a pig farm suspected to be infected with Seneca virus in Heilongjiang province, the whole gene sequence of the porcine Seneca virus CH-HLJ strain is shown as SEQ ID No.1, and the microorganism preservation number of the porcine Seneca virus CH-HLJ strain is CGMCC No. 18851. The invention further provides a method for preparing the inactivated vaccine for the Seneca virus disease, which comprises the following steps: (1) inactivating viruses after proliferation; (2) heating the vaccine adjuvant to obtain an oil phase; (3) heating the virus liquid to obtain a water phase; (5) mixing the oil phase and the water phase, and emulsifying to obtain a two-phase oil emulsion. The results of pig immunity experiments show that the porcine Seneca virus inactivated vaccine prepared by the invention can stimulate organisms to generate high-level antibodies. The result of the evaluation of the immune protection efficacy of the inactivated vaccine shows that the inactivated vaccine prepared by the invention can provide good protection against the attack of the porcine Seneca virus.
BACKGROUND: It is important to note that the causative agents and patterns of antibiotic resistance vary between urinary tract infections (UTIs) acquired in the community and those acquired in a hospital setting. Therefore, the aim of this study was to compare the types of organisms and patterns of antibiotic resistance in adult patients with community-acquired urinary tract infections (CA-UTIs) and hospital-acquired urinary tract infections (HA-UTIs).
METHODS: Retrospectively, we collected urine samples from patients at An-Najah National University Hospital who experienced nonrecurring urinary tract infections (UTIs) between January 2019 and December 2020. The data were subsequently analyzed using IBM-SPSS® 21.0 software to determine the distribution of microorganisms and evaluate the rates of antibiotic resistance.
RESULTS: A total of 798 nonrepetitive UTI patients were included in our study, in which more than half of the UTIs occurred in female patients (472; 59.1%), and most of the UTIs were of community origin (611; 76.6%). Both community-acquired urinary tract infections (CA-UTIs) and hospital-acquired urinary tract infections (HA-UTIs) were more common in female patients (45.6% and 13.5%, respectively). Escherichia coli was the most commonly isolated urinary pathogen in both the CA-UTIs and HA-UTIs. The five most common isolated urinary pathogens were E. coli, Klebsiella pneumoniae, Enterococcus faecalis, E. faecium, and Pseudomonas aeruginosa. Among the isolated bacteria, 28.2% were extended-spectrum beta-lactamase (ESBL)-producing bacteria, 4.1% were carbapenem-resistant Enterobacterales (CRE), and 6.5% were vancomycin-resistant Enterococci. The most commonly isolated urinary pathogens from HA-UTIs showed higher resistance rates against all the tested antibiotics except for E. faecium, which showed greater resistance to tetracycline (42.5%) and quinupristin/dalfopristin (17.5%) in CA-UTIs.
CONCLUSIONS: There are similarities in the etiological profiles of CA-UTI and HA-UTI, but the resistance rates are high, and urine culture is essential for the correct treatment of individual cases, even in primary care.
Ureteral stents are commonly used in the field of urology to maintain urinary drainage and are inserted into ureters of patients who suffer from kidney stones, urinary tract infections or cancer. Usually the muscle cells of the ureter contract in a coordinated fashion (peristalsis) in order to provide urinary flow from the kidney into the bladder. By inserting a stent these contractions are disrupted, eventually resulting in a loss of peristalsis. This phenomena is accompanied by swelling of the kidney and pain, which are well-known negative side effects of stents. To avoid stent-related morbidity and improve patients care this issue needs to be investigated further. A first step is to analyse the impact of stents on peristalsis and to possibly bring these results into context with hypothesised molecular mechanisms involved in peristalsis.
All owners/managers of small businesses in 10 control neighborhoods will will receive a request to support youth physical activity. None of the other components of the treatment arm (e.g., direct support to specific programs, advisory board) will be provided.
Exhaustion disorder (ED) is a stress-related disorder characterized by physical and mental symptoms of exhaustion. Recent data suggest that pathophysiological processes in the central nervous system are involved in the biological mechanisms underlying ED. The aims of this study were to investigate if plasma levels of neuro-related proteins differ between patients with ED and healthy controls, and, if so, to investigate if these differences persist over time. Using the Olink Neuro Exploratory panel, we quantified the plasma levels of 92 neuro-related proteins in 163 ED patients at the time of diagnosis (baseline), 149 patients at long-term follow-up (7-12 years later, median follow-up time 9 years and 5 months), and 100 healthy controls. We found that the plasma levels of 40 proteins were significantly higher in the ED group at baseline compared with the control group. Out of these, the plasma levels of 36 proteins were significantly lower in the ED group at follow-up compared with the same group at baseline and the plasma levels of four proteins did not significantly differ between the groups. At follow-up, the plasma levels of two proteins were significantly lower in the ED group compared with the control group. These data support the hypothesis that pathophysiological processes in the central nervous system are involved in the biological mechanisms underlying ED.
Application of miR-4491 in preparation of medicine for treating breast cancer. The invention provides a miRNA marker, which is miR-4491. The invention utilizes NCBI GEO data to search out a breast cancer minRA data set and a breast cancer mRNA data set which meet the requirements, analyzes the data sets and screens miRNA-miR-4491 closely related to breast cancer. miR-4491 can be used for judging breast cancer risk. Tests prove that miR-4491 can effectively distinguish a breast cancer sample from a normal sample. On the basis, miR-4491 can also be used for preparing medicines for inhibiting breast cancer proliferation or invasion. The invention provides a new idea for the molecular mechanism research of breast cancer, provides a new diagnosis method for clinically diagnosing breast cancer metastasis on a molecular level, and provides a new drug target for breast cancer treatment.
PURPOSE:An ameliorant of circulation, consisting of at least one of anthocyanin and anthocyanidin as a food colorant and having ameliorant action on circulation, e.g. diuretic, hypotensive and coronary arterial vasodilator action, etc., and high safety. CONSTITUTION:An ameliorant of circulation containing at least one of anthocyanin and anthocyanidin as an active constituent. The anthocyanin and anthocyanidin can be advantageously obtained from a cultivated cell of a higher plant, particularly Euphorbia milli Ch. de Moulins of the genus Euphorbia by a method described in the Japanese patent application No.57-2697, etc. The active constituent has ameliorant action on circulation, e.g. diuretic, hypotensive, coronary arterial vasodilator action and ameliorant action of cerebral circulation, etc. The ameliorant is administered in 10-20mg/kg/day as an oral drug an 1-4mg/kg/day as an intravenous injection.
FIELD: medicine.SUBSTANCE: invention relates to a composition for the delivery of nucleic acids. The composition contains (a) a cationic peptide or polymer; (b) a cationic or permanently cationic lipidoid compound; and (c) a nucleic acid compound. In this case, the specified cationic or permanently cationic lipidoid compound contains a central nitrogen atom connected with С2-3alkylene groups with three groups of Formula IIa and/or Formula IIb: -N(R1)-CH2-CH(R5)-R2(Formula IIa), -N+(R3)(R4)-CH2-CH(R5)-R2(Formula IIb), and independently for each individual group of Formula IIa or Formula IIb R1is selected from hydrogen or C1-C4-alkyl, R2is selected from linear C6, С8or С10-alkyl or branched, saturated, or unsaturated C6-C16hydrocarbyl chain, R3and R4are selected from C1-C4-alkyl and R5is a hydrogen or hydroxyl. The specified cationic peptide or polymer is a compound containing at least one cationic group P, containing at least one group-SH, capable of forming a disulfide bond, or its disulfide-coupled multimer. Group P is selected from a polymer group having a molecular weight of 0.5 kDa to 30 kDa, or a peptide group consisting of 3-100 amino acids, with at least 10% of the total amino acids of the specified peptide group being the main amino acids selected from Arg, Lys, His and/or Orn. The invention also relates to nanoparticles for the delivery of nucleic acids containing the specified composition, a set for the preparation of the composition, a vaccine and a method of delivery and RNA to the eye.EFFECT: invention provides high efficiency of the composition, and ability to deliver nucleic acids to mammalian cells.34 cl, 11 dwg, 8 tbl, 11 ex
Acute kidney injury (AKI) is a critical condition often associated with systemic inflammation and dysregulated gut microbiota. This study aimed to investigate the effects of the C5a receptor antagonist W54011 on lipopolysaccharide (LPS)-induced AKI, focusing on the colon's C5a/C5a receptor pathway, intestinal barrier integrity, and gut microbiota. Our findings demonstrate that W54011 effectively ameliorated kidney injury in the LPS-induced AKI model by selectively inhibiting the colon's C5a/C5a receptor signalling pathway. Additionally, C5a receptor blockade resulted in the inhibition of colonic inflammation and the reconstruction of the intestinal mucosal barrier. Furthermore, W54011 administration significantly impacted the composition and stability of the gut microbiota, restoring the abundance of dominant bacteria to levels observed in the normal state of the intestinal flora and reducing the abundance of potentially harmful bacterial groups. In conclusion, W54011 alleviates LPS-induced AKI by modulating the interplay between the colon, gut microbiota, and kidneys. It preserves the integrity of the intestinal barrier and reinstates gut microbiota, thereby mitigating AKI symptoms. These findings suggest that targeting the colon and gut microbiota could be a promising therapeutic strategy for AKI treatment.
Our sample consisted of 11 women with fibromyalgia enrolled according to the criteria of the American College of Rheumatology (ACR). Participants were underwent to clinical and electrophysiological assessments using the McGill Pain Questionnaire, the Hospital Anxiety and Depression Scale, and qEEG in frontal (F3, F4, Fz, F7, F8) and central (C3, C4,Cz) areas. qEEG data was collected with patients in resting eyes-closed: the relative spectral power of the frequency bands delta, theta, alpha and beta was evaluated.
The systems and methods are provided that can efficiently and accurately generate 3D printed vascular models of a vascular network, including stenotic pulmonary arteries, capable of vascular perfusion. The method may include acquiring image(s) of an anatomy of interest that includes a target area. The method may further include generating a geometric model of a phantom of a vascular network to be bioprinted using the image(s). The phantom may include vascular segment(s), inlet(s), and outlet(s). Each inlet and each outlet may communicate with at least one vascular segment. The method may include generating a geometric model of a bioreactor to be 3D printed based on the geometric model of the phantom using one or more of assembly parameters, phantom parameters, or any combination thereof. The bioreactor model may include inlet(s), outlet(s), a chamber in which the phantom is disposed, an outer housing, and an interface bordering the chamber.
TT alone will receive conventional treadmill training with no feedback from the system. They will train with a safety harness 18 sessions (3 times per week x 6 weeks).
OBJECTIVES: To investigate the membranous urethral length (MUL) measurement and its interobserver agreement, and propose literature-based recommendations to standardize MUL measurement for increasing interobserver agreement. MUL measurements based on prostate MRI scans, for urinary incontinence risk assessment before radical prostatectomy (RP), may influence treatment decision-making in men with localised prostate cancer. Before implementation in clinical practise, MRI-based MUL measurements need standardization to improve observer agreement.
METHODS: Online libraries were searched up to August 5, 2022, on MUL measurements. Two reviewers performed article selection and critical appraisal. Papers reporting on preoperative MUL measurements and urinary continence correlation were selected. Extracted information included measuring procedures, MRI sequences, population mean/median values, and observer agreement.
RESULTS: Fifty papers were included. Studies that specified the MRI sequence used T2-weighted images and used either coronal images (n = 13), sagittal images (n = 18), or both (n = 12) for MUL measurements. 'Prostatic apex' was the most common description of the proximal membranous urethra landmark and 'level/entry of the urethra into the penile bulb' was the most common description of the distal landmark. Population mean (median) MUL value range was 10.4-17.1 mm (7.3-17.3 mm), suggesting either population or measurement differences. Detailed measurement technique descriptions for reproducibility were lacking. Recommendations on MRI-based MUL measurement were formulated by using anatomical landmarks and detailed descriptions and illustrations.
CONCLUSIONS: In order to improve on measurement variability, a literature-based measuring method of the MUL was proposed, supported by several illustrative case studies, in an attempt to standardize MRI-based MUL measurements for appropriate urinary incontinence risk preoperatively.
CLINICAL RELEVANCE STATEMENT: Implementation of MUL measurements into clinical practise for personalized post-prostatectomy continence prediction is hampered by lack of standardization and suboptimal interobserver agreement. Our proposed standardized MUL measurement aims to facilitate standardization and to improve the interobserver agreement.
KEY POINTS: • Variable approaches for membranous urethral length measurement are being used, without detailed description and with substantial differences in length of the membranous urethra, hampering standardization. • Limited interobserver agreement for membranous urethral length measurement was observed in several studies, while preoperative incontinence risk assessment necessitates high interobserver agreement. • Literature-based recommendations are proposed to standardize MRI-based membranous urethral length measurement for increasing interobserver agreement and improving preoperative incontinence risk assessment, using anatomical landmarks on sagittal T2-weighted images.
Maintenance Therapy 

The efficacy of ziprasidone as adjunctive therapy to lithium or valproate in the maintenance treatment of bipolar I disorder was established in a placebo-controlled trial in patients who met DSM-IV criteria for bipolar I disorder. The trial included patients whose most recent episode was manic or mixed, with or without psychotic features. In the open-label phase, patients were required to be stabilized on ziprasidone plus lithium or valproic acid for at least 8 weeks in order to be randomized. In the double-blind randomized phase, patients continued treatment with lithium or valproic acid and were randomized to receive either ziprasidone (administered twice daily totaling 80 mg to 160 mg per day) or placebo. Generally, in the maintenance phase, patients continued on the same dose on which they were stabilized during the stabilization phase. The primary endpoint in this study was time to recurrence of a mood episode (manic, mixed or depressed episode) requiring intervention, which was defined as any of the following: discontinuation due to a mood episode, clinical intervention for a mood episode (e.g., initiation of medication or hospitalization), or Mania Rating Scale score ≥ 18 or a MADRS score ≥18 (on 2 consecutive assessments no more than 10 days apart). A total of 584 subjects were treated in the open-label stabilization period. In the double-blind randomization period, 127 subjects were treated with ziprasidone, and 112 subjects were treated with placebo. Ziprasidone was superior to placebo in increasing the time to recurrence of a mood episode. The types of relapse events observed included depressive, manic, and mixed episodes. Depressive, manic, and mixed episodes accounted for 53%, 34%, and 13%, respectively, of the total number of relapse events in the study.
INTRODUCTION: Cohort evidence of the association of diabetes mellitus (DM) with chronic kidney disease (CKD) is limited. Previous studies often describe patients with kidney disease and diabetes as diabetic kidney disease (DKD) or CKD, ignoring other subtypes. The present study aimed to assess the prospective association of diabetes status (no diabetes, pre-diabetes, screened diabetes, previously diagnosed controlled/uncontrolled diabetes with/without antidiabetic treatment) and random plasma glucose (RPG) with CKD risk (including CKD subtypes) among Chinese adults.
RESEARCH DESIGN AND METHODS: The present study included 472 545 participants from the China Kadoorie Biobank, using baseline information on diabetes and RPG. The incident CKD and its subtypes were collected through linkage with the national health insurance system during follow-up. Cox regression models were used to calculate the HR and 95% CI.
RESULTS: During 11.8 years of mean follow-up, 5417 adults developed CKD. Screened plus previously diagnosed diabetes was positively associated with CKD (HR=4.52, 95% CI 4.23 to 4.83), DKD (HR=33.85, 95% CI 29.56 to 38.76), and glomerulonephritis (HR=1.66, 95% CI 1.40 to 1.97). In those with previously diagnosed diabetes, participants with uncontrolled diabetes represented higher risks of CKD, DKD, and glomerulonephritis compared with those with controlled RPG. The risk of DKD was found to rise in participants with pre-diabetes and increased with the elevated RPG level, even in those without diabetes.
CONCLUSIONS: Among Chinese adults, diabetes was positively associated with CKD, DKD, and glomerulonephritis. Screen-detected and uncontrolled DM had a high risk of CKD, and pre-diabetes was associated with a greater risk of DKD, highlighting the significance of lifelong glycemic management.
Arginine stimulation test: 5 grams of arginine hydrochloride intravenously. Performed at baseline after mixed meal tolerance test (MMTT), performed separately at day -1 or 0, day 1, day 3, day 7 and 3 months, and also at 3 months after MMTT.
As the 23S rRNA mutation guided selection of antimicrobial agent, patients infected with strains without mutation of 23S rRNA are assigned to this arm. In this arm, they are treated with vonoprazan 20 mg bid, amoxicillin 750 mg bid and clarithromycin 200 mg bid for 1 week for the eradication of H. pylori.
The patients in the Con group had the electrodes applied at the same acupoints, but received no stimulation. Anesthesia was induced i.v. with propofol (2 mg kg-1) and remifentanil (1 μg kg-1) using a target-controlled infusion (TCI) system. After loss of consciousness, vecuronium (0.1 mg kg-1) was administered i.v. Patients' lungs were mechanically ventilated in a volume-controlled mode with a tidal volume of 8ml kg-1 body weight during the operation.
Use of Butorphanol Tartrate Nasal Spray as the First Opioid Analgesic 

Factors to be considered in determining the dose are age, body weight, physical status, underlying pathological condition, use of other drugs, type of anesthesia to be used, and surgical procedure involved. Use in the elderly and in patients with hepatic or renal disease requires extra caution [see PRECAUTIONS and CLINICAL PHARMACOLOGY: Individualization of Dosage]. The following doses are for patients who do not have impaired hepatic or renal function and who are not on CNS active agents. 

Use for Pain: Initiate treatment with Butorphanol Tartrate Nasal Spray in a dosing range of 1 mg (1 spray in one nostril) to 2 mg (1 spray in each nostril) every 3 to 4 hours as needed for pain, at the lowest dose necessary to achieve adequate analgesia. Titrate the dose based upon the individual patient’s response to their initial dose of Butorphanol Tartrate Nasal Spray. The usual recommended dose for initial nasal administration of Butorphanol Tartrate Nasal Spray is 1 mg (1 spray in one nostril). Adherence to this dose reduces the incidence of drowsiness and dizziness. If adequate pain relief is not achieved within 60 to 90 minutes, an additional 1 mg dose may be given. 

The initial dose sequence outlined above may be repeated in 3 to 4 hours as required after the second dose of the sequence. 

Depending on the severity of the pain, an initial dose of 2 mg (1 spray in each nostril) may be used in patients who will be able to remain recumbent in the event drowsiness or dizziness occurs. In such patients single additional 2 mg doses should not be given for 3 to 4 hours. 

Use in Balanced Anesthesia: The use of Butorphanol Tartrate Nasal Spray is not recommended because it has not been studied in induction or maintenance of anesthesia. 

Labor: The use of Butorphanol Tartrate Nasal Spray is not recommended as it has not been studied in labor. 

Conversion from Other Opioids to Butorphanol Tartrate Nasal Spray 

There is inter-patient variability in the potency of opioid drugs and opioid formulations. Therefore, a conservative approach is advised when determining the total daily dosage of Butorphanol Tartrate Nasal Spray. It is safer to underestimate a patient’s 24-hour Butorphanol Tartrate Nasal Spray dosage than to overestimate the 24-hour butorphanol dosage and manage an adverse reaction due to overdose.